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HigH-grade gliomas (HGGs) are associated with a poor prognosis despite maximal treatment with combination therapy involving surgery, chemo-
therapy, and radiotherapy.26 Some retrospective studies 
and one prospective study have suggested a significant 
effect of extent of resection on survival of patients with 
these aggressive tumors.7,11,13,21 It is, however, difficult to 
distinguish viable tumor tissue at the margins of resection 
during surgery,29 and complete removal, defined as sur-
gical excision of the entire enhancing mass, is therefore 
difficult to achieve. Studies have shown it to be feasible 
in only a small proportion of cases.11,13 Technical tools, 
such as neuronavigation,32 intraoperative MRI (iMRI),6,15 
and ultrasonography,30 have been applied in an effort to 
improve surgical results, but only iMRI has been stud-
ied with specific application to glioma surgery in a ran-
domized trial. The results of this trial provided Class I 
evidence for the effect of this technique on extent of re-
section.19 However, no difference in progression-free sur-
vival (PFS) was found between the two groups included 
in this study.19 In addition, iMRI-guided surgery can take 
significantly more time, and can interfere with the surgical 
workflow (for example, because of issues regarding com-
patibility of instruments or equipment) depending on the 
sort of iMRI technology used.6 Photodynamic detection of 
the tumor, which takes advantage of a photosensitive drug 
specific for the tumor tissue and with a well-defined fluo-
rescence, has been used in neurosurgery during removal 
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Object. Fluorescein, a dye that is widely used as a fluorescent tracer, accumulates in cerebral areas where the 
blood-brain barrier is damaged. This quality makes it an ideal dye for the intraoperative visualization of high-grade 
gliomas (HGGs). The authors report their experience with a new fluorescein-guided technique for the resection of 
HGGs using a dedicated filter on the surgical microscope.
Methods. The authors initiated a prospective Phase II trial (FLUOGLIO) in September 2011 with the objective 
of evaluating the safety of fluorescein-guided surgery for HGGs and obtaining preliminary evidence regarding its 
efficacy for this purpose. To be eligible for participation in the study, a patient had to have suspected HGG amenable 
to complete resection of the contrast-enhancing area. The present report is based on the analysis of the short- and 
long-term results in 20 consecutive patients with HGGs (age range 45–74 years), enrolled in the study since Septem-
ber 2011.
In all cases fluorescein (5–10 mg/kg) was injected intravenously after intubation. Tumor resection was per-
formed with microsurgical technique and fluorescence visualization by means of BLUE 400 or YELLOW 560 filters 
on a Pentero microscope.
Results. The median preoperative tumor volume was 30.3 cm3 (range 2.4–87.8 cm3). There were no adverse 
reactions related to fluorescein administration. Complete removal of contrast-enhanced tumor was achieved in 80% 
of the patients. The median duration of follow-up was 10 months. The 6-months progression-free survival rate was 
71.4% and the median survival was 11 months.
Conclusions. Analysis of these 20  cases suggested that fluorescein-guided technique with a dedicated filter on 
the surgical microscope is safe and allows a high rate of complete resection of contrast-enhanced tumor as determined 
on early postoperative MRI. Clinical trial registration no.: 2011-002527-18 (EudraCT).
(http://thejns.org/doi/abs/10.3171/2013.11.FOCUS13487)
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of HGGs. In particular, the utilization of 5-aminolevulinic 
acid (5-ALA), a natural biochemical precursor of hemo-
globin that evokes synthesis and accumulation of fluores-
cent porphyrins in some kinds of tumors, including glio-
mas, has been shown to be useful during surgical removal 
of HGGs,22,24,25 and it has been shown to increase the rates 
of complete resection and 6-month PFS in a randomized 
trial.23 However, some limitations were found with this 
technique: the drug should be administered orally 2.5 to 
3.5 hours before induction of anesthesia; it is recommend-
ed not to expose the patient to sunlight or strong room 
light for 24 hours after administration because of the risk 
of skin sensitization;29 and 5-ALA is expensive (approxi-
mately 900 Euros per vial). 
Fluorescein sodium, the sodium salt of fluorescein, 
provides an attractive alternative for fluorescence-guided 
resection of HGGs. It is far less expensive than 5-ALA (ap-
proximately 5 Euros per 1-g vial) and has been extensively 
used intravenously as a diagnostic tool to perform retinal 
angiography, with a very low rate of side effects.9,10,16,33 
Due to its ability to penetrate areas of the brain where 
the blood-brain barrier has been disrupted, it has been 
used with the purpose of localizing brain tumors during 
open biopsy since 1948.14 In addition, the feasibility of 
fluorescein-guided removal of HGGs has been suggested 
by the results of several studies.8,18,20 The results of one 
prospective study suggested a possible improvement of 
the extent of resection using fluorescein, although in that 
study surgery was performed without a specific filter in-
tegrated into the surgical microscope.5 In 2011, our group 
started the first prospective Phase-II trial with the aid of 
a microscope-integrated fluorescence kit (FLUOGLIO) 
to evaluate the safety of and obtain initial data about the 
efficacy of fluorescence-guided resection of HGGs. The 
study was based on Simon’s two-stage design. In 2013, we 
reported the preliminary short-term results in 12 cases of 
glioblastoma (GBM).1
In the present paper we analyzed the short and long-
term results of fluorescein-guided resection using a dedi-
cated filter on the surgical microscope in the first 20 pa-
tients with HGGs enrolled in the FLUOGLIO study.
Methods
Patients
The inclusion criteria of the FLUOGLIO trial were as 
follows: 1) age 18 to 75 years; 2) suspected, newly diag-
nosed, untreated HGGs (with the tentative diagnosis be-
ing based on brain MRI with and without contrast and 
with volumetric sequences); 3) tumor location allowing 
for complete resection of contrast-enhancing area as de-
termined by the surgeon. The exclusion criteria were: 1) a 
histological diagnosis other than HGG (anaplastic astro-
cytoma [AA] or GBM); 2) a tumor that originated in the 
midline, basal ganglia, cerebellum, or brainstem; 3) mul-
ticentric tumors; 4) the presence of a large, non–contrast-
enhancing area, suggesting low-grade glioma with malig-
nant transformation; 5) medical reasons precluding MRI 
(for example, the presence of a pacemaker); 6) inability 
to give consent because of dysphasia or language barrier; 
7) Karnofsky Performance Status (KPS) score of 60 or 
less; 8) renal insufficiency; 9) hepatic insufficiency; and 
10) history of active malignant tumors at any other site.
The study started in September 2011, when the first 
patient was enrolled. Written informed consent was ob-
tained from all patients. The FLUOGLIO study was 
approved by the Ethics Committee of the Foundation 
IRCCS Neurological Institute Carlo Besta of Milan and 
registered on the European Regulatory Authorities web-
site (EudraCT no. 2011-002527-18).
Twenty-two patients (16 male and 6 female) were 
screened for participation in this prospective trial. The pa-
tients’ age ranged from 45 to 74 years (median 66 years). 
Two patients were excluded due to histological diagnoses 
other than HGG (lymphoma in 1 case and primitive neu-
roectodermal tumor in the other). Twenty patients were 
finally enrolled (19 with GBM and 1 with AA).
Clinical and neurological characteristics of the pa-
tients are summarized in Table 1.
Clinical and Radiological Assessment
The KPS was used to record the patients’ general 
physical status both pre- and postoperatively. Data from 
laboratory tests were also recorded. The patients’ neuro-
logical function was assessed by means of the Mini Men-
tal State Evaluation (MMSE) and the National Institutes 
of Health Stroke Scale (NIHSS). Clinical assessment con-
sisted of a preoperative visit within 14 days of surgery and 
an immediate postoperative evaluation within the first 72 
hours after surgery.
All patients underwent MRI studies with a 1.5-T 
Siemens scanner with and without the use of a contrast 
agent. In all cases volumetric sequences were included. 
The preoperative MRI studies were performed within 4 
days of surgery, and the postoperative studies within the 
first 72 hours after surgery. The preoperative tumor vol-
ume and the postoperative residual tumor volume were 
calculated by an independent neuroradiologist (C.B.), us-
ing open-source software (Osirix for Macintosh, www.
osirix-viewer.com). Residual tumor was defined as an area 
of contrast-enhancement with a calculated volume greater 
than 0.175 cm3.23
After surgery, all patients were treated according to 
the Stupp protocol with radiotherapy and concomitant te-
mozolomide therapy.27 No restrictions were imposed on 
treatment after disease progression. Any further treatment 
after the Stupp protocol (that is, second-line chemother-
apy, additional surgery and radiosurgery) was recorded. 
Patients underwent clinical and radiological follow-
up examinations within 4 weeks after the end of radioche-
motherapy and then every 2 months (for GBM patients) 
or every 3 months (for the patient with AA). The clini-
cal evaluation included the same tests performed at the 
preoperative and early postoperative evaluations. Imaging 
follow-up included MRI with and without contrast agent, 
including volumetric sequences (Siemens 1.5 T).
We defined progression at follow-up MRI as the ap-
pearance of a new contrast-enhancing area greater than 
0.175 cm3 or an increase in residual tumor based on the 
RANO criteria.31
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Because general anesthesia was used for surgery, im-
mediate and postoperative reactions to the administration 
of fluorescein could be evaluated only for objective find-
ings, such as hypotension, cardiac arrest, shock, seizures, 
bronchospasm, or anaphylaxis.
Surgical Protocol
Our surgical protocol of fluorescein-guided technique 
has been described in a previous report of the preliminary 
results of the FLUOGLIO trial.1
Briefly, after intubation and before skin incision, pa-
tients received 5–10 mg/kg of a 20% solution of sodium 
fluorescein (Monico Spa, Italy), administered intrave-
nously. A dedicated surgical microscope (Pentero with 
fluorescence kit, BLU 400 or YELLOW 560, Carl Zeiss) 
was used during the surgical procedure. For the first 6 
cases, we used the same fluorescence kit as for 5-ALA–
guided glioma resection (BLU 400). A new fluorescence 
kit, YELLOW 560, became available in January 2012 and 
was used in subsequent cases. This kit was specifically 
designed by the Carl Zeiss Company for excitation in the 
wavelength range of 460–500 nm and for observation in 
the wavelength range of 540–690 nm. Consequently, it 
was possible to reduce the fluorescein dosage to 5 mg/kg. 
Neuronavigation was allowed only for surgical planning, 
initial tumor localization, and orientation during tumor 
removal, but not for judgment regarding extent of resec-
tion. Ultrasonography was not used. For tumors located 
in or close to eloquent areas, neurophysiological monitor-
ing was performed following our usual protocol.2 During 
resection, the microscope could be switched alternatively 
from fluorescent to white-light illumination, as desired 
by the surgeon, by pressing the specific button on the mi-
croscope handgrip. However, with the YELLOW 560 fil-
ter, as already described, it was possible to visualize the 
fluorescent signal and at the same time the nonfluorescent 
tissue in more natural color.1 For this reason, most of the 
surgery was completed with the filter activated. Tumor re-
section was completed in an inside-out fashion, usually 
by ultrasonic aspiration, until all the fluorescent tissue ex-
posed was removed, as considered feasible by the surgeon 
(Figs. 1 and 2).
Histological Analysis and MGMT Methylation Status
Histological analysis of the tumors was performed in 
a standard manner and tumors were classified according 
to the 2007 WHO classification by an independent neuro-
pathologist (B.P.).12,17 For patients who had tumors in non-
eloquent areas and gave their specific written informed 
consent, biopsies were performed at the tumor margin to 
evaluate the accuracy of fluorescein in identification of tu-
mor tissue. Four biopsy specimens were obtained at the 
tumor margin in areas located distant from each other—2 
in the fluorescent tissue and 2 in the nonfluorescent tis-
sue—to calculate sensitivity and specificity (as described 
in Statistical Analysis, below). In these cases, histological 
analysis was performed by a pathologist who was blind 
to the fluorescence characteristics of the biopsies, to dis-
criminate between clear tumor tissue and peritumor area 
(gliosis or tumor cell infiltration), also performing immu-
nohistochemistry for GFAP (glial fibrillary acidic protein) 
and for the proliferation index with Ki 67 (MIB 1).
TABLE 1: Clinical characteristics of the patients included in FLUOGLIO study from September 2011 to June 2013
Case No. Tumor Location Tumor Size (cm3) Histology MGMT Status % of Resection
NIHSS KPS Score
Preop Postop Preop Postop
 1 lt occipital 28.0 GBM unmethylated 100 3  4  70  60
 2 lt temporal 12.8 GBM methylated 100 0  0 100 100
 3 rt parietal 49.8 GBM unmethylated 100 3  4  70  80
 4 rt parietal 87.8 GBM methylated 99.9 7  8  70  60
 5 rt frontal 12.2 GBM unmethylated 100 0  1  90  80
 6 lt occipital 41.0 GBM unmethylated 100 0  0 100 100
 7 lt temporoinsular 31.8 GBM unmethylated 88.6 1  2  90  80
 8 lt frontoinsular 34.5 GBM unmethylated 100 4 13  90  50
 9 rt frontal 9.6 GBM unmethylated 82.8 0  3  90  70
10 lt temporal 2.4 AA methylated 100 1  1  90  90
11 rt frontal 20.0 GBM unmethylated 100 1  1  90  90
12 rt frontal 83.8 GBM unmethylated 100 2  1  80  90
13 rt temporal 86.1 GBM unmethylated 100 1  0  70  80
14 rt parietal 12.5 GBM unmethylated 100 1  4 100  90
15 rt frontal 69.7 GBM unmethylated 100 2  5  70  50
16 lt frontal 8.3 GBM unmethylated 100 1  2  90  70
17 rt frontal 31.8 GBM methylated 100 0  0 100 100
18 rt frontal 8.9 GBM unmethylated 100 0  0  90  90
19 lt temporal 28.8 GBM unmethylated 100 1  2  80  70
20 rt parietal 38.9 GBM unmethylated 99.3 1  2  90  80
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Methylation patterns in the CpG islands of O-6-meth-
ylguanine-DNA methyltransferase (MGMT) were also 
ana lyzed.4
Statistical Analysis
The sample size and stopping rules of the FLUO-
GLIO trial have been described in a previous report.1
The sample was described by means of the usual de-
scriptive statistics: mean, median, and standard deviation 
for continuous variables and proportions for categorical 
ones. The Student t-test was used to compare pre- and 
post operative clinical status.
Sensitivity and specificity were calculated to evalu-
ate fluorescein accuracy in tumor identification as follows. 
Sensitivity was calculated as the number of true-positive 
fluorescent samples (histologically confirmed HGG)/all 
sam ples with confirmed HGG. Specificity was calculated 
as the number of true-negative nonfluorescent samples 
(his tologically confirmed as not neoplastic)/all samples 
his tologically confirmed as not neoplastic.
Progression-free survival (PFS) was calculated from 
the time of surgery until disease progression or death/last 
follow-up, if censored. Six-month PFS was defined as the 
proportion of patients without radiological progression at 
the 6th month after surgery. Overall survival (OS) was 
calculated from treatment onset until death or last follow-
up, if censored; PFS and OS were estimated by the Ka-
plan-Meier method.
Results
Intraoperative Fluorescence Characteristics
The mechanism of action of fluorescein is related to 
the passage through a damaged blood-brain barrier and 
accumulation in extracellular space. Thus, it helps in visu-
alizing the pathological tissue in the same way as contrast 
enhancement during MRI.
We injected fluorescein after patient intubation and 
before skin incision. In this way, we believed that we could 
avoid accumulation of fluorescein in cerebral areas inad-
vertently damaged during craniotomy or dural opening. 
The microscope is brought into the operative field after 
craniotomy. At the activation of the filter, the dura ap-
peared fluorescent due to the characteristic features of its 
vascularization (Figs. 1 and 2). Tumor tissue showed an 
intense fluorescence, even if some necrotic parts of tumors 
appeared darker. Sometimes, in cases of partly cystic le-
sions, the liquid inside the cyst was intensively fluorescent 
and leaked during resection until full aspiration.
Regarding the 2 filters, as already described in our 
preliminary experience, both the BLU 400 and YEL-
LOW 560 modules of the Zeiss microscope allowed a 
good discrimination between the fluorescent and nonfluo-
rescent tissue.1 In fact, due to the wide range of emission 
and excitation, even the BLU 400 filter, which was used in 
the first 6 cases, allowed a clear visualization of the light 
emitted by fluorescein in the area of blood-brain barrier 
disruption. The main difference between the two filters 
was related to the fact that, due to the higher specificity 
of YELLOW 560 module, the fluorescent tissue appeared 
greener and brighter, with a dose of fluorescein that was 
Fig. 1. Case 18. A and B: Intraoperative view during resection of 
a right frontal GBM. With the YELLOW 560 filter activated (A) it is pos-
sible to visualize an area of tumor that needs to be removed (red arrow); 
the same view is shown with white light illumination (B), with the tumor 
tissue indicated by a black arrow. Note in A (right part of the picture) the 
reflected dural flap appearing fluorescent (see text) C: Preoperative 
axial T1-weighted MR image obtained after intravenous administra-
tion of a contrast agent showing a right frontal GBM (tumor volume 
8.93 cm3). D: Early postoperative (< 48 hours after surgery) axial T1-
weighted MR image obtained after contrast administration showing a 
complete tumor resection without any area of contrast enhancement.
Fig. 2. Case 16. A and B: Intraoperative view during resection of 
a left frontal GBM. At the end of the resection with the YELLOW 560 
filter activated (A) there is no more fluorescent area visible; the same 
view is also shown with white light illumination (B). Note in A (right part 
of the picture) that the reflected dural flap is still fluorescent after tumor 
removal (see text). C: Preoperative axial T1-weighted MR image ob-
tained after contrast administration showing a left frontal GBM (tumor 
volume 8.26 cm3). D: Early postoperative (< 48 hours after surgery) 
contrast-enhanced axial T1-weighted MR image showing a complete 
tumor resection without any area of contrast enhancement.
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reduced by half. In addition, due to the specific YELLOW 
560 module characteristics,1 the nonfluorescent tissue ap-
peared in more natural color, without significant differ-
ences between the oculars of the first surgeon and those 
of the assistant (Fig. 1). This reduced eye fatigue during 
surgery. Furthermore, in this way, most of the procedure 
could be performed under filter activation, reducing the 
discomfort of switching continuously between white light 
and fluorescence illumination to control bleeding or ma-
nipulate vessels during tumor resection.
Percentage of Resection
The median preoperative tumor volume was 30.3 cm3 
(range 2.4–87.8 cm3). Complete removal of all enhanc-
ing tumor as verified by an early postoperative MRI was 
achieved in 16 cases (80%) (Fig. 3 and Table 1). In the 
remaining cases the mean extent of tumor resection was 
92.6% (range 82.8%–99.9%) (Fig. 4 and Table 1).
Accuracy of Fluorescein in Tumor Identification
A total of 36 biopsies (18 in fluorescent tissue and 
18 in nonfluorescent tissue) were performed at the tumor 
margin in 9 patients (4 biopsies in each patient). Sixteen 
of the 18 biopsies of fluorescent areas showed clear HGG 
tissue. Seventeen of the 18 biopsies of nonfluorescent ar-
eas showed the absence of HGG tissue. These data were 
confirmed by immunohistochemical analysis, as previ-
ously reported.1 Therefore, we obtained a sensitivity and 
a specificity of fluorescein in identifying tumor tissue, re-
spectively, of 94% and 89.5%.
Reactions to Fluorescein, Postoperative Neurological 
Status, and Complications
No adverse reaction to fluorescein administration was 
registered in this cohort of patients, including those with 
different histological diagnoses who were excluded from 
the analysis, although, as described above, only objective 
findings could be recorded due to the fact that patients 
were in a state of general anesthesia during surgery.
No statistically significant difference was found be-
tween preoperative and immediate postoperative NIHSS 
scores (1.45 ± 0.38 vs 2.65 ± 0.71, p = 0.148) and KPS 
scores (median 90 vs 80, p = 0.145).
In the early postoperative period (during the first 
postoperative month), complications were observed in 3 
cases. One patient with left occipital GBM (Case 1) de-
veloped an entrapped temporal horn 16 days after surgery 
and underwent ventriculoperitoneal shunt insertion. One 
patient with left frontoinsular GBM (Case 8) developed 
an infarction in the internal capsule causing hemiplegia 
and aphasia; the patient partially recovered after intensive 
postoperative rehabilitation. One patient with right frontal 
GBM (Case 18) had a postoperative infection of the bone 
flap, requiring wound revision and antibiotic therapy.
Progression-Free and Overall Survival
Fifteen of 20 patients completed the Stupp protocol 
postoperatively. After a median follow-up of 10 months 
(range 3–25 months), the estimated 6-month PFS was 
71.4% (60.6%–82.2%) (Fig. 5). Eleven patients died dur-
ing the follow-up period as a result of tumor progression 
(10 cases) or an unrelated cause (myocardial infarction in 
1 case, Case 15). The estimated median survival was 11 
months (Fig. 6).
Discussion
Our data in this cohort of patients confirmed that the 
use of intravenous fluorescein during resection of HGGs 
is safe and showed that it was associated with a high rate 
of complete resection of contrast-enhanced tumor at the 
early postoperative MRI.
As already suggested by our preliminary analysis 
of a subgroup of patients with GBM1 and based on the 
known safety profile of fluorescein, no adverse reaction 
related to the use of this agent has been recorded so far 
in the FLUOGLIO study. This might be related also to 
the use of specific filters that enable reduction of the total 
dose of fluorescein injected1,8,18 with a possible impact on 
reduction of side effects. Rare adverse events, including 
anaphylactic reactions, after fluorescein injection have 
been reported in the ophthalmological and neurosurgi-
cal literature,3,9,10,16,28,33 but no side effects were registered 
with the use of low-dose fluorescein in more recent pa-
Fig. 3. Case 2. A: Preoperative axial T1-weighted MR obtained 
after contrast administration showing a left posterior temporal GBM 
(tumor volume 12.8 cm3). B: Early postoperative (< 48 hours after 
surgery) axial T1-weighted MR image obtained after contrast admin-
istration showing a complete tumor resection without any area of con-
trast enhancement. C and D: Follow-up contrast-enhanced axial 
T1-weighted MR image obtained 24 months after surgery showing no 
tumor recurrence.
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pers. In addition, it should be noticed that in neurosurgical 
applications, side effects may be even less frequent than in 
ophthalmological cases due to the fact that fluorescein is 
administered with the patient intubated in a state of gen-
eral anesthesia.
The volumetric analysis performed in our cohort of 20 
patients with HGGs on early postoperative MRI showed 
a total resection of the contrast-enhancing tissue in 80% 
of cases. These data confirmed the results of our previous 
preliminary analysis of 12 cases.1 Although still limited 
by the small number of cases and, more importantly, the 
absence of a control group of patients undergoing surgery 
without fluorescein, the results were promising. The inclu-
sion and exclusion criteria were in fact similar to those of 
the prospective Phase III trial on 5-ALA by Stummer et 
al.23 Specifically, we enrolled patients who had tumors in 
locations that allowed for complete resection of the con-
trast-enhanced area. In a control group of patients from 
the 5-ALA study, operated on without the aid of fluores-
cent visualization, a complete resection was reported to 
be feasible only in 36% of the cases.23 However, it should 
be emphasized that the accumulation of fluorescein in the 
brain tumor area is related to the passage through a dam-
aged blood-brain barrier, and not to a specific uptake by 
the high-grade glial cells, as for 5-ALA. Therefore, this 
could lead to a reduced accuracy with respect to tumor 
identification.29 Nevertheless, different studies performed 
with and without filters on the surgical microscope have 
shown a high level of accuracy in tumor identification.8 
These data were confirmed by our analysis of biopsies of 
fluorescent and nonfluorescent tissue at the tumor margin, 
with a sensitivity and specificity in tumor identification of 
94% and 89.5%, respectively. The use of a specific filter on 
the surgical microscope could have led to better accuracy 
in tumor identification. This could also explain why the 
patients did not experience a statistically significant dif-
ference in neurological function in the postoperative pe-
riod. In addition, the new filter, YELLOW 560, allowed a 
dose reduction of fluorescein, due to the higher specificity 
of the filter characteristics. Theoretically, this could fur-
ther reduce the number of side effects. Furthermore, this 
filter allowed an optimal delineation of fluorescent tissue, 
together with a good visualization of the peritumoral area 
in more natural colors, thus allowing the surgeon to com-
plete most of the procedure without the need to switch the 
microscope illumination to normal white light, as happens 
during 5-ALA–guided resection (Figs. 1 and 2).
The median duration of long-term follow-up (10 
months) is still not sufficient to draw a definitive conclu-
sion about long-term outcome. However, preliminary data 
Fig. 5. Kaplan-Meier curve of progression-free survival. Fig. 6. Kaplan-Meier curve of overall survival.
Fig. 4. Case 20. A: Preoperative axial T1-weighted MR image obtained after contrast administration showing a right frontal 
GBM (tumor volume 38.92 cm3). B and C: Early postoperative (< 48 hours after surgery) axial T1-weighted MR image obtained 
after contrast administration showing a very extensive, but not complete tumor removal (red arrow in C); the residual tumor 
volume was 0.28 cm3.
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on 6-month PFS were promising, with more than 70% of 
patients showing no disease progression.
Conclusions
Based on the data collected in these 20 patients, the 
use of intravenous fluorescein during surgery for HGGs 
with a dedicated filter integrated into the surgical micro-
scope appears safe and able to allow a high rate of com-
plete resection. If confirmed at the end of the study, these 
results will represent the prerequisite to build up a proper 
prospective randomized controlled Phase III trial to de-
finitively prove a positive effect of intravenous fluorescein 
on extent of resection of HGGs.
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